Whilst the induction of IL‐13 has been associated with reduced ACE2 expression and viral entry [29, 30], and Th2 cytokines could potentially be beneficial in mucosal immunity [31], IL‐13 has also been suggested to be a predictor for COVID‐19 severity in humans [32] and mouse models [30], with IL‐13 blockade increasing the activity and polyfunctionality of CD8+ T cell responses in both vaccination settings [33, 34] and upon Influenza infection [35, 36]. The gene discussed is ACE2; the disease is COVID-19.